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Variation in the apolipoprotein E gene (APOE) has been reported to be associated with longevity in humans. The
authors assessed the allelic distribution of APOE isoforms ’2, ’3, and ’4 among 10,623 participants from 15 case-
control and cohort studies of age-related macular degeneration (AMD) in populations of European ancestry (study
dates ranged from 1990 to 2009). The authors included only the 10,623 control subjects from these studies who
were classiﬁed as having no evidence of AMD, since variation within the APOE gene has previously been asso-
ciated with AMD. In an analysis stratiﬁed by study center, gender, and smoking status, there was a decreasing
frequency of the APOE ’4 isoform with increasing age (v2 for trend ¼ 14.9 (1 df); P ¼ 0.0001), with a concomitant
increase in the ’3 isoform (v2 for trend ¼ 11.3 (1 df); P ¼ 0.001). The association with age was strongest in ’4
homozygotes; the frequency of ’4 homozygosity decreased from 2.7% for participants aged 60 years or less to
0.8% for those over age 85 years, while the proportion of participants with the ’3/’4 genotype decreased from
26.8% to 17.5% across the same age range. Gender had no signiﬁcant effect on the isoform frequencies. This
study provides strong support for an association of the APOE gene with human longevity.
aged; apolipoprotein E2; apolipoprotein E3; apolipoprotein E4; apolipoproteins E; longevity; meta-analysis;
multicenter study
Abbreviations: AMD, age-related macular degeneration; APOE, apolipoprotein E gene; Arg, arginine; Cys, cysteine; LDL, low
density lipoprotein; SNP, single nucleotide polymorphism.
The human apolipoprotein E gene (APOE; OMIM
107741), located on chromosome 19q13.2, is central to
the metabolism of low density lipoprotein (LDL) cholesterol
and triglycerides and has been associated with increased risk
of a variety of complex and age-related disorders (1). These
include coronary heart disease events (2), atherosclerosis
(3), age-related macular degeneration (AMD) (4), Alzheimer’s
disease (5), and other dementias (6). The small, multifunc-
tional apolipoprotein E lipid transport protein acts as a ligand
for the LDL receptor and is also involved in the maintenance
and repair of neuronal cell membranes in the central and pe-
ripheral nervous systems. Variation in 2 single nucleotide
polymorphisms (SNPs) within the APOE gene, rs429358
and rs7412, results in different isoforms reported to exert op-
posite effects in relation to the metabolism of coronary heart
disease-related blood products such as LDL cholesterol and
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triglycerides (3, 7, 8). The allelic variants derived from these
SNPs are commonly referred to as e2, e3, and e4 and are
differentiated on the basis of cysteine (Cys) and arginine
(Arg) residue interchanges at positions 112 and 158 in the
amino acid sequence. The 3 variants give rise to 6 biallelic
genotypes (e3/e3, e3/e4, e2/e3, e4/e4, e2/e4, and e2/e2,
ranked from most to least common among European pop-
ulations (3)). The e2 allele has a cysteine residue at positions
112 and 158 in the receptor-binding region of apolipopro-
tein E. The e3 allele has residues Cys-112 and Arg-158, and
the e4 allele has arginine residues at both positions. These
amino acid substitutions have strong physiologic conse-
quences for protein function.
Life expectancy in Western countries has risen by 3
months per year over the past 160 years, with a net increase
of approximately 40 years within this time frame, largely as
a consequence of reductions in malnutrition and childhood
infection (9). A number of reports on human longevity have
shown that the frequency of the e4 allele is lower in older
age groups, such as octogenarians, nonagenarians, and cen-
tenarians, than in younger or middle-aged persons (10) and
that absence of an e4 allele appears to be a favorable sur-
vival factor. In populations of European origin, an elevated
mortality risk has been reported for the e3/e4 genotype rel-
ative to the e3/e3 genotype, with a slightly decreased risk
being associated with the e2/e3 genotype (11, 12). Further-
more, a gender-specific survival effect associated with e2
has been reported, although whether this is specific to males
or females is as yet unclear, with opposing associations with
both genders being reported (13, 14).
The analyses undertaken in this study were subsidiary to a
pooled data analysis assessing APOE variation in the con-
text of AMD. The authors examined the association of
APOE with age as a marker for longevity and assessed the
potential for a gender-specific effect.
MATERIALS AND METHODS
Study population
The data originated from 15 studies carried out at 40
study centers in 11 countries: 9 in Europe (United Kingdom,
Germany, Netherlands, Norway, Estonia, Italy, France,
Greece, and Spain), the United States, and Australia, which
had previously examined the association of APOE with
AMD (15–28). The dates of the studies ranged from 1990
to 2009. Analysis was restricted to samples derived from
participants of European descent (n ¼ 24,774). Individual
participant data, including age, gender, smoking status (ever
smoker vs. never smoker), and APOE genotype, were avail-
able for 23,686 persons, enabling us to conduct a pooled data
analysis. The Alzheimer’s disease status of these participants
was not available. We restricted the analysis to 10,623 par-
ticipants with no evidence of any AMD, classified by means
of retinal photography or clinical examination, in order to
avoid confounding by disease status due to a prior association
of variation within the APOE gene and AMD (4). Investiga-
tors from 3 studies—the Rotterdam Study, the Women’s
Health Initiative Sight Exam Study, and the European Eye
Study—provided data derived from samples acquired
through population-based surveys (n ¼ 7,023). The remain-
der of the data came from case-control (association) studies.
Data on age at examination, gender, smoking status (ever
vs. never), APOE genotype, and AMD phenotype were re-
quested from each contributing center (Table 1). All of the
studies were approved by local ethics review boards, and
each participant provided written informed consent prior to
recruitment. Recruitment procedures and detailed AMD
grading methods for each study center have been described
previously (15–28).
Statistical analysis
Both SNPs were assessed for departure from Hardy-
Weinberg equilibrium by study, using a v2 goodness-of-fit
test. Data were categorized on the basis of age into 8 groups
(60, 61–65, 66–70, 71–75, 76–80, 81–85, 86–90, and >90
years). Separate analyses were performed for each of the 3
APOE alleles in the data set. Logistic regression was used to
assess the variation in APOE allele frequencies across age
groups, with center, gender, and smoking included in the
regression to adjust for possible confounding. A likelihood
ratio v2 test was used to compare models that included and
excluded a linear term for age group, thus providing a test
for trend in allele frequency across age groups. This analysis
also provided an odds ratio summarizing the change in odds
for each allele per 5-year increase in age. Interactions be-
tween gender and age and between center and age were also
tested in the logistic regression using likelihood ratio tests
which compared models that included and excluded the
interaction terms.
RESULTS
APOE allele frequency with age
No departure from Hardy-Weinberg equilibrium was de-
tected for either SNP by center or within the entire data set.
APOE allele frequencies varied between studies (data not
shown), with ranges of 6.7%–10.0% (APOE e2), 75.3%–
82.8% (APOE e3), and 7.5%–15.6% (APOE e4). APOE
genotype frequencies for the 10,623 controls are shown in
Table 2. The frequency of the e4 allele decreased from
17.6% to 8.3% (9.3%) with increasing age, while the fre-
quency of the e3 allele increased from 73.3% to 83.3%
(þ10.0%) (Table 3, Figure 1). Following adjustment for
center and smoking status to limit potential confounding,
we observed a significant decrease in the frequency of e4
with increasing age (v2 ¼ 14.9 (1 df); P ¼ 0.0001), repre-
senting a 5% decrease in odds per 5-year increase in age
(odds ratio ¼ 0.95, 95% confidence interval: 0.92, 0.97), as
well as a significantly increased frequency of e3 (v2 ¼ 11.3
(1 df); P¼ 0.001), representing a 4% increase in odds per 5-
year increase in age (odds ratio ¼ 1.04, 95% confidence
interval: 1.02, 1.07). The frequency of the e2 allele showed
little variation with age. The relations between allele fre-
quency and age in males and females were compared by
including an age 3 gender interaction in the logistic regres-
sion analysis, but none of the interactions were signifi-
cant (likelihood ratio v2 test: e2, P ¼ 0.13; e3, P ¼ 0.25; e4,
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P ¼ 0.80). Tests of age 3 center interactions were also
conducted and showed no evidence of heterogeneity in
age effects by center (likelihood ratio v2 test: e2,P¼ 0.21; e3,
P ¼ 0.88; e4, P ¼ 0.38).
Although the number of persons who were homozygous
for the e4 isoform was low at 1.9% (Table 2), the age-related
effect observed was most prominent in e4 homozygotes,
with a 70% reduction in frequency from 2.7% in persons
aged 60 years or less to 0.8% in those over age 85 years
(Table 2). A decreased frequency of 35% was also observed
in e3/e4 heterozygotes, with a reduction from 26.8% to
17.5% recorded over the same age range (Table 2). Persons
who were heterozygous for the e2/e4 genotype showed a
nonsignificant change of 0.7% in frequency within this
age range, from 3.1% to 2.4% (Table 2).
DISCUSSION
In previous studies, investigators have reported increased
mortality associated with the e4 allele of the APOE gene,
and this has been partly attributed to the increased risk this
Table 1. Sample Size, Age Distribution, and Gender Composition Among Control Subjects From Contributing
Studies in a Pooled Analysis of Variations in APOE Allele Frequencies With Age (n ¼ 10,623), 1990–2009
First Author, Year
(Reference No.)




McKay, 2009 (22) Belfast, Northern Ireland 436 74.8 (6.9) 49–102 38.1
Fritsche, 2009 (15) Regensburg, Germany 553 76.2 (5.3) 65–97 38.0
Francis, 2009 (17) Portland, Oregon (US) 272 73.9 (6.4) 60–92 44.1
van Leeuwen, 2004 (20) Rotterdam, the Netherlands 3,805 67.5 (8.3) 55–99 42.2
Bergeron-Sawitzke, 2009 (16) AREDS, US 199 77.1 (4.6) 63–88 47.2
Baird, 2006 (18) Melbourne, Australia 106 71.5 (6.5) 60–86 45.3
Hadley, 2010 (24) Philadelphia, Pennsylvania (US) 379 75.6 (7.9) 56–96 46.4
Haan, 2006 (28) WHI-SE, US 1,283 73.7 (4.7) 65–86 0
Yates, 2007 (23) Edinburgh, United Kingdom 179 73.2 (7.8) 46–92 38.5
Ennis, 2008 (25) Southampton, United Kingdom 458 70.7 (9.3) 50–91 47.8
Conley, 2005 (21) Los Angeles, California (US) 142 72.5 (8.8) 50–91 43.7
Augood, 2004 (27) EUREYE, Europe 1,935 72.4 (5.3) 65–95 45.2
Zareparsi, 2004 (19) Ann Arbor, Michigan (US) 253 76.6 (5.3) 68–92 44.3
Yates, 2007 (23) Cambridge, United Kingdom 417 75.0 (7.8) 42–96 40.0
Dandekar, 2006 (26) London, United Kingdom 206 74.9 (7.7) 52–91 40.8
Total 10,623 71.5 (7.8) 42–102 37.7
Abbreviations: APOE, apolipoprotein E gene; AREDS, Age-Related Eye Disease Study; EUREYE, European Eye
Study; SD, standard deviation; US, United States; WHI-SE, Women’s Health Initiative Sight Exam.
Table 2. Distribution of APOE Genotypes by Age Group in a Pooled Analysis of Variations in APOE Allele




Total No.e2/e2 e2/e3 e2/e4 e3/e3 e3/e4 e4/e4
No. %a No. % No. % No. % No. % No. %
60 9 0.9 138 13.3 32 3.1 553 53.3 278 26.8 28 2.7 1,038
61–65 2 0.2 157 13.3 33 2.8 692 58.7 260 22.1 34 2.9 1,178
66–70 15 0.6 296 11.9 50 2.0 1,523 61.3 540 21.7 61 2.5 2,485
71–75 12 0.5 304 11.6 54 2.1 1,632 62.1 586 22.3 39 1.5 2,627
76–80 15 0.8 257 12.9 43 2.2 1,219 61.2 430 21.6 29 1.5 1,993
81–85 6 0.6 131 14.2 19 2.1 570 61.6 186 20.1 13 1.4 925
86–90 0 0.0 32 10.3 9 2.9 212 68.2 55 17.7 3 1.0 311
>90 0 0.0 11 16.7 0 0.0 44 66.7 11 16.7 0 0.0 66
Total 59 0.6 1,326 12.5 240 2.3 6,445 60.7 2,346 22.1 207 1.9 10,623
Abbreviation: APOE, apolipoprotein E gene.
a Row percentage.
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Table 3. Variation in APOE Allele Frequencies With Age in a Pooled Analysis (n ¼ 10,623), Overall and by Gender, 1990–2009
No. of Samples










No. % No. % No. % No. % No. % No. % No. % No. % No. %
Age group, years
60 1,038 188 9.1 116 9.5 72 8.4 1,522 73.3 891 73.2 631 73.5 366 17.6 211 17.3 155 18.1
61–65 1,178 194 8.2 124 9.4 70 6.8 1,801 76.4 1,004 75.7 797 77.4 361 15.3 198 14.9 163 15.8
66–70 2,485 376 7.6 246 8.3 130 6.5 3,882 78.1 2,303 77.4 1,579 79.1 712 14.3 425 14.3 287 14.4
71–75 2,627 382 7.3 238 7.1 144 7.7 4,154 79.1 2,671 79.2 1,483 78.9 718 13.7 465 13.8 253 13.5
76–80 1,993 330 8.3 219 8.2 111 8.4 3,125 78.4 2,085 78.4 1,040 78.3 531 13.3 354 13.3 177 13.3
81–85 925 162 8.8 111 9.2 51 7.9 1,457 78.8 949 79.0 508 78.4 231 12.5 142 11.8 89 13.7
86–90 311 41 6.6 24 6.1 17 7.5 511 82.2 323 81.6 188 83.2 70 11.3 49 12.4 21 9.3
>90 66 11 8.3 7 8.1 4 8.7 110 83.3 73 84.9 37 80.4 11 8.3 6 7.0 5 10.9
Total 10,623 1,684 7.9 1,085 8.2 599 7.5 16,562 78.0 10,299 77.8 6,263 78.2 3,000 14.1 1,850 14.0 1,150 14.4
Trend testa
v2 0.03 0.20 0.06 11.3 8.84 3.29 14.9 10.2 5.43
P value 0.86 0.65 0.80 0.001 0.003 0.07 1.1 3 104 0.001 0.02
Change per 5-year increaseb
Odds ratio 1.00 0.99 1.01 1.04 1.05 1.04 0.95 0.94 0.95
95% conﬁdence interval 0.96, 1.03 0.95, 1.04 0.95, 1.07 1.02, 1.07 1.02, 1.08 1.00, 1.08 0.92, 0.97 0.91, 0.98 0.90, 0.99
Abbreviation: APOE, apolipoprotein E gene.
a v2 tests for trend (1 df) in APOE allele frequency with age, with adjustment for confounding by study, gender, and smoking status, were generated by means of logistic regression performed
separately for each allele.










































isoform poses in relation to coronary heart disease, athero-
sclerosis, Alzheimer’s disease, and other dementias (1–3, 5–
7). Various hypotheses have been proposed surrounding the
functionality of this small, multifunctional lipid transport
protein, particularly through its role as a ligand for LDL
cholesterol and triglycerides and its involvement in the
maintenance and repair of neuronal cells. The APOE iso-
forms generated from the different alleles interact differ-
ently with the lipoprotein receptors, leading to altered
cholesterol levels. High levels of LDL cholesterol are asso-
ciated with APOE e4, low levels with e2, and intermediate
levels with e3 (29). However, the exact mechanisms regard-
ing the association of APOE with increased mortality, and
indeed its association with a variety of disease and patho-
logic processes conferring increased or decreased risk, have
yet to be elucidated.
A study by Seripa et al. (13) suggested an association of
decreased mortality with the e2 allele in males only, partic-
ularly in relation to dementia and cardiovascular disease
(n ¼ 1,710; 757 males). Another smaller independent study
(14) suggested that the reduced mortality associated with e2
was specific to women, and thus there is some confusion
with regard to the direction and magnitude of any potential
gender difference. To our knowledge, our study was one of
the largest to assess the relation between APOE and age to
date, and we found no evidence to suggest that the association
with age and APOE was different in women compared with
men; therefore, our results do not suggest that differences in
longevity between men and women are explained by APOE.
Other studies with smaller sample sizes have found lower
rates of mortality associated with e2 relative to e3 with age
(12, 30), but our data did not support these findings, with a
small but nonsignificant variation in the relation of e2 with
age being observed. However, with only 66 participants over
age 90 years in this study, this age category was not well
represented. This may explain why previous findings of an
increased e2 allele frequency in the elderly were not con-
firmed in this study. Furthermore, our results did not show
an effect of interaction between age and AMD phenotype on
APOE allele frequency prevalence, indicative that the ob-
served effect occurs independently of AMD (data not shown).
Note that e4 has been previously reported to exert a protective
effect against AMD (4, 15, 31, 32), and as such, an inflated
frequency of this allele may be represented within the AMD-
free control samples used in this study, compared with the
frequency actually present in the general population.
Our findings offer further support to recently reported
findings implicating the APOE region in longevity (33).
Although the platform used in the study by Sebastiani
et al. (33) did not genotype either rs429358 or rs7412 di-
rectly, an intronic SNP rs2075650, located in a gene called
TOMM40, was used as a strong proxy for rs429358, as the 2
SNPs have previously been shown to be in strong linkage
disequilibrium (34). The high level of linkage disequili-
brium which exists between TOMM40 and APOE makes it
difficult to identify the causal variant associated with the
effect observed at this locus (34). Sebastiani et al. (33) also
assessed the association of this region with longevity for an
interaction with gender but could find no evidence to sup-
port effect modification.
Our results show that variation in control allele frequen-
cies needs to be carefully considered in relation to associa-
tion studies of age-related conditions. Failure to do so will
result in serious confounding, with an impact on unadjusted
association studies that is often not appreciated; many in-
vestigators assume that frequencies are constant across the
life span, and this is especially so when the incidence of the
disease in question increases with age (35). It has been
estimated from cross-sectional studies that the frequency
distribution of the e4 allele halves between the ages of 60
and 85 years (35), and this is supported by the current study.
A decrease in the frequency of e4 is likely to occur as a
consequence of increased risk associated with this allele in
relation to coronary heart disease, atherosclerosis,
Alzheimer’s disease, and other dementias (1). Association
studies of age-related disorders investigating the effects of
genes that may be influenced by longevity may yield greater
variation in allele frequencies between controls alone than
between cases and controls. While adjustment for age is im-
perative to limit confounding under these circumstances, cau-
tion is recommended in considering associations such as that
for APOE, in case-control studies that are not well-matched
for age.
The magnitude of the effect measured and the associated
level of significance will be limited by sample size and the
allele frequencies present within the population in question,
which varies significantly in the case of APOE. APOE allele
frequencies measured in this investigation (data not shown)






























Figure 1. Allele frequency distribution of apolipoprotein E gene
(APOE) e2, e3, and e4 isoforms by age group in 10,623 subjects with
European ancestry, 1990–2009.
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82.8% for e3, and 7.5% and 15.6% for e4. Geographic var-
iation in APOE allele frequencies has been reported previ-
ously, with a resultant impact on statistical power (36–38). It
was not possible for us to ascertain the geographic origin of
each participant individually within this study, but adjust-
ment for potential confounding by study bias/location was
incorporated into our analyses to assess the relation between
APOE and age. Since it was not possible to genotype
markers that were informative for ancestry in these samples,
we cannot rule out the possibility that population stratifica-
tion could have made some contribution to our findings.
Adjustment for center partly addressed some of the issues
raised by Lewis and Brunner (30) with respect to population
stratification and variation in genotype frequencies. Further-
more, individual smoking status data were available for sub-
jects, although adjustment for this lifestyle risk factor failed
to have any significant impact on the associations inferred.
The statistical analyses for measuring the effects of gender
and age in the current study were performed on categorized
data, which were arbitrarily grouped into 5-year intervals
prior to undertaking the analysis. The data from this study
support a 5% reduction in the odds for the e4 allele every 5
years beyond the age of 60 years, while the associated odds
for the e3 allele increased by 4% across the same time period.
Narrower and broader age intervals were assessed, with little
change in terms of the significance of the effect observed, as
was the case when age was treated as a continuous variable.
Limitations of our study to accurately assess the role of
APOE in longevity pertain to the impact associated with this
gene on debilitating diseases such as coronary heart disease,
atherosclerosis, or age-related disorders, such as Alzheimer’s
disease and other dementias. Persons who are affected by
such diseases may be less likely to participate in a case-
control study. In addition, AMD was ruled out in our study
subjects, which could also have had some effect, since APOE
has been reported to be associated with AMD in previous
studies (4, 15, 31, 32). We suspect that these effects would
have been small, but ideally a prospective population-based
study with a sufficient sample size and follow-up would be
best placed to offer an unbiased and accurate reflection on the
role of APOE in longevity.
The current study strongly supports the association of
APOE alleles with human longevity by demonstrating varia-
tion in APOE allele frequencies in older persons and illus-
trates the potential confounding effect of age in association
studies on APOE. The underlying mechanism behind the
association of APOE with age remains to be elucidated.
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